This move is archived. Current quotes and coverage live on the stock page.
Get APTX alerts:
Apotex Health Corp's stock surged by over 7% in the latest trading session, reflecting strong market confidence and positive analyst sentiment.
In a notable trading day, Apotex Health Corp (APTX.TO) experienced a significant uptick, closing at CA$38.17, a 7.22% increase from the previous session. This surge comes on the heels of recent strategic developments and analyst endorsements that have bolstered investor optimism.
Advertisement
Apotex Health Corp
APTX.TO
APTX.TO
Apotex Health Corp
WealthAwesomeMarket cap
$7.67B
52W high
$40.18
52W low
$26.05
1W change
-3.56%
Analyst Price Targets
Based on analyst covering APTX
Wall Street analysts forecast APTX stock price to rise 25.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$41.34
+25.1% Upside
Current Price
C$33.06
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APTX's historical volatility
30-Day Vol
44.7%
Annualized
90-Day Vol
49.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$39.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$35.09 | C$30.08 – C$40.93 |
| 60 trading days | C$37.24 | C$29.95 – C$46.31 |
| 90 trading days | C$39.52 | C$30.27 – C$51.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the implications of Apotex's strategic transactions and analyst ratings as indicators of potential growth and market positioning.
Apotex Health Corp Surges 7.22% in One Day
With a market cap of CA$8.71 billion, Apotex's strong performance reflects growing investor confidence following key strategic moves.
Bull case
Apotex is well-positioned for sustained growth thanks to its recent strategic transactions and product approvals. This makes it an appealing choice for investors looking to invest in the healthcare sector.
Bear case
While the stock is gaining momentum, investors should be cautious of potential market volatility and competition in the pharmaceutical sector, which could impact Apotex's stock performance.
Advertisement
Recent Developments Fueling Growth
Apotex has recently completed a strategic transaction with Cumberland Pharmaceuticals, integrating their U.S. branded businesses. This move is expected to enhance Apotex's market presence and product offerings, contributing to the stock's positive performance. Additionally, the approval of SEVMIA™, a generic semaglutide for weight management, positions the company favorably in a growing market.
Analyst Sentiment and Market Reactions
Analyst coverage from firms like Stifel and RBC Capital has further bolstered confidence in Apotex, with both firms assigning positive ratings and price targets above the current trading price. This endorsement from analysts is a strong signal to investors, suggesting that Apotex is on a solid growth trajectory. For more insights, check out our detailed analysis on APTX.TO.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
